2 results
Approved WMOCompleted
To demonstrate the additive IOP lowering effect of SIMBRINZA (dosed BID) when added to DUOTRAV solution in subjects with open-angle glaucoma or ocular hypertension.
Approved WMOCompleted
Studies to date have demonstrated a reduction in HF-related hospitalizations and improved quality of life in patients using the CardioMEMS HF System when compared with patients receiving standard of care in the United States. The purpose of this…